{"entity":{"id":"nct05566041","kind":"trial","name":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer","aka":["REPLATINUM"],"tldr":"A phase 3 trial of Etoposide, Carboplatin and Cisplatin in small-cell lung cancer, run by EpicentRx, Inc., active and no longer recruiting.","summary":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05566041 by EpicentRx, Inc., with 292 participants enrolled, started 2022-08-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: RRx-001 + eLOOP Device and Cisplatin/carboplatin plus etoposide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05566041","url":"https://clinicaltrials.gov/study/NCT05566041"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["etoposide","carboplatin","cisplatin"],"companies":["epicentrx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05566041","phase":"3","setting":"REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer","sponsor":"EpicentRx, Inc.","participation":[{"nct":"NCT05566041","source":"https://clinicaltrials.gov/study/NCT05566041","fetchedAt":"2026-10-07T16:53:46.156Z","studySha256":"53a9db28285cd3dccb67c0650663d55605263138eee357f2b7537083ca2c24dc","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2024-10-31","leadSponsor":"EpicentRx, Inc.","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":292,"enrolmentType":"ESTIMATED","siteCount":2,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2022-08-01","startedType":"actual","enrolled":292,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05566041/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"}],"company":[{"id":"epicentrx","kind":"company","name":"EpicentRx","route":"/companies/epicentrx/"}]}}